Apollon Formularies (AQSE:APOL) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Apollon Formularies's cash to debt ratio for the quarter that ended in Jun. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Apollon Formularies could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Apollon Formularies's Cash-to-Debt or its related term are showing as below:

AQSE:APOL' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 11 years, Apollon Formularies's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

AQSE:APOL's Cash-to-Debt is ranked better than
99.81% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.92 vs AQSE:APOL: No Debt

Apollon Formularies Cash-to-Debt Historical Data

The historical data trend for Apollon Formularies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Apollon Formularies Cash-to-Debt Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial											No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Apollon Formularies's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollon Formularies's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Cash-to-Debt falls into.

Apollon Formularies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Apollon Formularies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Apollon Formularies had no debt ⁽¹⁾.

Apollon Formularies's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Apollon Formularies had no debt ⁽¹⁾.

Apollon Formularies (AQSE:APOL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Apollon Formularies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.